Reviews/SGLT2 Inhibitors/SGLT2 inhibitors reduce CV death and HF hospitalisation in HFpEF
· SG-HP-01 · v2
Borderline: within 4 points of the Established/Likely boundary, so a re-grade could land either side.
Two large, separate drug trials tested whether this class of medicines helps people whose hearts pump with a preserved or only mildly reduced squeeze. Both trials, using different drugs from different makers, found fewer combined events of dying from heart causes or being hospitalised for heart failure [8] [4]. The benefit held up across patients with and without kidney disease [7] and across body weights [9]. The main caveat is that almost all of the benefit came from fewer heart-failure hospitalisations, not from fewer heart deaths: looking at heart death on its own, the effect was not statistically convincing [4] [8]. The panel treated the replicated combined result as strong but held back from the top tier because the death part of the claim is not independently supported and only two placebo-controlled trials underpin it.
Two independent double-blind placebo-controlled RCTs in ejection fraction over 40% reduced the registered composite of cardiovascular death or heart-failure hospitalisation: empagliflozin HR 0.79 (95% CI 0.69-0.90, P<0.001) [8] and dapagliflozin HR 0.82 (95% CI 0.73-0.92, P<0.001) [4]. In EMPEROR-Preserved the effect was 'mainly related to a lower risk of hospitalization for heart failure' [8], and in DELIVER cardiovascular death alone was HR 0.88 (95% CI 0.74-1.05) [4]. The effect was consistent across chronic kidney disease status [7] and across BMI categories [9]. A retrospective propensity-matched cohort in HFpEF with ESRD pointed the same direction on all-cause mortality (HR 0.49, 95% CI 0.43-0.55) and ADHF (HR 0.72, 95% CI 0.67-0.77) [10]. The contested point: The division is whether the claim's naming of 'CV death' is supported: the composite is reduced and replicated, but the cardiovascular-death component alone is not individually significant in either pivotal trial [4] [8]. The corpus also rests on only two placebo-controlled RCTs, with [7] and [9] being subgroup re-analyses of one of them rather than independent trials.
All 20 papers behind this claim with their DOIs and what each does to it, the panel’s arbitration, the evidence gap map and the open research questions. Free, and sent to your inbox.
We’ll also send you other claims from SGLT2 Inhibitors, one at a time, and tell you when a release or a pivotal trial changes a grade. Unsubscribe by replying.
One reviewer's only job is to attack the finding. The challenges below were weighed before the grade was set.
The claim names CV death as a reduced outcome, but in DELIVER [4] CV death alone was HR 0.88 (95% CI 0.74-1.05, not significant) and in EMPEROR-Preserved [8] the effect was 'mainly related to a lower risk of hospitalization for heart failure'. The composite is carried by HFH; reading the claim as reducing each component independently is overreach.
The composite rests on only two placebo-controlled RCTs; [7] and [9] are subgroup re-analyses of the same EMPEROR-Preserved trial, so they confirm but do not independently extend the evidence base.
Where it remains uncertain. Cardiovascular death alone was not individually significant (DELIVER HR 0.88, 95% CI 0.74-1.05 [4]; EMPEROR-Preserved effect 'mainly related to' reduced HF hospitalisation [8]), so the mortality half of the claim is weaker than the composite.
Aleatory
Cardiovascular death alone in DELIVER gave HR 0.88 with a 95% CI of 0.74-1.05 that crosses 1 [4], so sampling variation leaves its direction unresolved.
The load-bearing papers from a corpus of 20, each classified by what it does to the claim. Every DOI is taken from the corpus the claim was graded on.
Independent pivotal RCT with a second molecule replicating the composite benefit.
“cardiovascular death occurred in 231 patients (7.4%) and 261 patients (8.3%), respectively (hazard ratio, 0.88; 95% CI, 0.74 to 1.05).”
Panel auditInternal validity: high · scope of inference: SGLT2i effect on the composite outcome in HF with LVEF >40% (HFmrEF and HFpEF).Key limitations: includes HFmrEF (EF >40%), not HFpEF only · CV death component not individually significant
Confirms composite benefit is consistent across kidney function.
“Irrespective of CKD status, empagliflozin reduced the primary outcome (with CKD: hazard ratio [HR] 0.80, 95% confidence interval [CI] 0.69-0.94; without CKD: HR 0.75, 95% CI 0.60-0.95; interaction p = 0.67)”
Panel auditInternal validity: high · scope of inference: Empagliflozin effect on the CV death/HHF composite in HFpEF across kidney function.Key limitations: subgroup analysis of a single trial · composite driven by HHF component
Pivotal RCT: empagliflozin reduces the composite CV death or HHF in EF>40%, driven by HFH.
“a primary outcome event occurred in 415 of 2997 patients (13.8%) in the empagliflozin group and in 511 of 2991 patients (17.1%) in the placebo group (hazard ratio, 0.79; 95% confidence interval [CI], 0.69 to 0.90; P<0.001). This effect was mainly related to a lower risk of hospitalization for heart failure in the empagliflozin group.”
Panel auditInternal validity: high · scope of inference: Empagliflozin effect on the CV death/HHF composite in HF with EF >40%.Key limitations: includes EF >40% (HFmrEF overlap) · effect mainly from HHF component
The abstract reports KCCQ, 6MWT, weight and biomarker endpoints and does not report CV death or HF hospitalization.
Panel auditInternal validity: medium · scope of inference: Effect of 12-week dapagliflozin on symptoms and exercise function in chronic HFpEF.Key limitations: no CV death/HHF endpoint · small sample · 12-week duration
4 of 20 papers shown. The full review lists all of them, with the panel’s arbitration →
Claims are graded at each quarterly release, and re-graded between releases only when a pivotal trial lands. Every change is a new version of the claim.
Replicated pivotal-RCT support for the composite endpoint falls just short of Established because the claim's CV-death component is not independently significant and the corpus rests on only two placebo-controlled trials.
Release 2026-q4 re-graded every claim from its corpus under protocol v0.19. An earlier release's grade is shown for the record; it came from an earlier protocol and is not a movement.
Assumptions that carry weight but are not themselves established.
The panel records the gap that would most move the claim, and the study that would close it.
CV death as a standalone endpoint. The claim names CV death but in both trials it is not individually significant [4] [8], so the mortality half is the weakest link. The panel rates this the highest-importance open gap for the claim, and names the study design that would close it: A trial or pooled analysis prospectively powered for cardiovascular death in EF>40% populations.
Open question: Do SGLT2 inhibitors reduce cardiovascular death alone in HFpEF, independent of the composite? Why it is still open: DELIVER CV death was HR 0.88 (95% CI 0.74-1.05) [4] and EMPEROR-Preserved's effect was mainly from reduced HF hospitalisation [8].
Priors is a sceptical first reader, not peer review, and not medical advice.
Release 2026-q4 · graded 23 Oct 2026 · protocol v0.19